Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2016 Aug 1;103:157-73. doi: 10.1016/j.addr.2016.01.013. Epub 2016 Jan 29.

Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Author information

1
Department of Microbiology and Immunology, Geisel School of Medicine, Lebanon, NH, USA.
2
Department of Microbiology and Immunology, Geisel School of Medicine, Lebanon, NH, USA; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. Electronic address: Margaret.e.ackerman@dartmouth.edu.

Abstract

A combination of advances spanning from isolation to delivery of potent HIV-specific antibodies has begun to revolutionize understandings of antibody-mediated antiviral activity. As a result, the set of broadly neutralizing and highly protective antibodies has grown in number, diversity, potency, and breadth of viral recognition and neutralization. These antibodies are now being further enhanced by rational engineering of their anti-HIV activities and coupled to cutting edge gene delivery and strategies to optimize their pharmacokinetics and biodistribution. As a result, the prospects for clinical use of HIV-specific antibodies to treat, clear, and prevent HIV infection are gaining momentum. Here we discuss the diverse methods whereby antibodies are being optimized for neutralization potency and breadth, biodistribution, pharmacokinetics, and effector function with the aim of revolutionizing HIV treatment and prevention options.

KEYWORDS:

Antibody; Effector function; HIV; Neutralization; Prevention; Therapy

PMID:
26827912
PMCID:
PMC4935580
DOI:
10.1016/j.addr.2016.01.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center